摘要
非小细胞肺癌是肺癌中最普遍的类型,其治疗过程充满挑战。近年来,新辅助免疫治疗作为一种创新的治疗手段,特别是程序性死亡受体1(PD-1)抑制剂,在非小细胞肺癌治疗领域显示出了卓越的临床效果。研究显示,PD-1抑制剂通过阻断免疫抑制机制,增强了机体对肿瘤细胞的免疫反应,进而提升了治疗效果。尽管如此,PD-1抑制剂在实际临床应用中仍面临着诸如个体反应差异、耐药以及患者选择标准不一等挑战。文章回顾了PD-1抑制剂在非小细胞肺癌新辅助免疫治疗中的研究进展,探讨其作用机制以及在临床实践中的应用情况。同时,文章还展望了新辅助免疫联合治疗的潜力,提出个体化治疗和免疫联合疗法可能进一步提高非小细胞肺癌治疗效果,优化治疗应用。
Non-small cell lung cancer is the most common type of lung cancer,and its treatment process is full of challenges.In recent years,neoadjuvant immunotherapy,as an innovative treatment approach,especially programmed death receptor 1(PD-1)inhibitors,has shown excellent clinical efficacy in the treatment of non-small cell lung cancer.Research has shown that PD-1 inhibitors enhance the body's immune response to tumor cells by blocking the immunosuppressive mechanism,thereby improving the therapeutic effect.However,PD-1 inhibitors still face challenges in practical clinical applications,such as individual response differences,drug resistance and inconsistent patient selection criteria.This article reviews the progress of PD-1 inhibitors in neoadjuvant immunotherapy for non-small cell lung cancer,explores their mechanism of action,and discusses their application in clinical practice.At the same time,the article also looks forward to the potential of neoadjuvant immunotherapy,proposing that individualized treatment and immunotherapy may further improve treatment efficacy of non-small cell lung cancer and optimize treatment applications.
作者
田恒溯
唐健
Tian Hengsu;Tang Jian(Department of Thoracic Surgery,Yantai Affiliated Hospital of Binzhou Medical College,Yantai 264100,China)
出处
《肿瘤研究与临床》
2025年第6期472-477,共6页
Cancer Research and Clinic
基金
山东省医学会临床科研资金-齐鲁专项(YXH2022ZX02033)
山东省中医药科技项目(M-2022234)。
关键词
癌
非小细胞肺
程序性死亡受体1
新辅助疗法
免疫疗法
Carcinoma,non-small-cell lung
Programmed death receptor 1
Neoadjuvant therapy
Immunotherapy
